HER2-negative breast cancer exhibits significant biological heterogeneity, particularly between HER2-low (IHC 1+ or 2+/in situ hybridization assay, ISH not amplified) and HER2-zero (IHC 0) subtypes (10). This evidence concerns the gene ERBB2 and breast cancer.